Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in nonvalvular atrial fibrillation

Marcel Levi MD

首页> 外文期刊>ACP Journal Culb >Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in nonvalvular atrial fibrillation

【24h】

Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in nonvalvular atrial fibrillation

机译：Ximelagatran在预防非瓣膜性房颤中预防中风和全身性栓塞的疗效不逊于华法林

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《ACP Journal Culb》 |2005年第1期|p.00000007-00000007|共1页
作者
Marcel Levi MD;
展开▼
作者单位

University of AmsterdamAmsterdam, The Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Piccini Jonathan P., Stevens Susanna R., Chang YuChiao, Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：对有关“非瓣膜性房颤患者中风和全身性栓塞的预测指标：肾功能不全：ROCKET AF（Rivaroxaban每日一次，口服，直接因素）中的R（2）CHADS（2）指数的验证的答复Xa抑制与维生素K拮抗剂在房颤预防卒中和栓塞试验中的比较以及ATRIA（房颤的抗凝和危险因素）研究队列”
2. Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Apostolakis Stavros, Lane Deirdre A., Banerjee Amitava Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：Acostolakis等人关于文章的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R（2）牧草（2）指数在火箭AF中的指数（Rivaroxaban曾经每日，口服，与维生素K拮抗剂相比，直接因子XA抑制预防心房颤动中的中风和栓塞试验）和阿里亚（心房颤动的抗凝和危险因素）研究队列“
3. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperati [J] . Yamaguchi T Stroke: A Journal of Cerebral Circulation . 2000,第4期

机译：华法林用于非瓣膜性房颤患者继发性卒中的最佳治疗强度：一项多中心，前瞻性，随机试验。日本非瓣膜性心房颤动-代谢二级预防合作社
4. Warfarin Underuse for Nonvalvular Atriai Fibrillation: How to Adjust Our Aims? [C] . G. DI PASQUALE, E. CERE, A. LOMBARDI International Workshop on Cardiac Arrhythmias . 2004

机译：Warfarin Filluse for Nonvalular Atriai颤动：如何调整我们的目标？
5. Dabigatran versus warfarin for the prevention of stroke in patients with chronic nonvalvular atrial fibrillation. [D] . Qiu, Fen. 2011

机译：达比加群与华法林预防慢性非瓣膜性房颤患者的中风。
6. For people with non-valvular atrial fibrillation rivaroxaban isnon-inferior to warfarin for preventing stroke or embolism with no differencein the risk of clinically relevant bleeding [O] . Matthew Sherwood, Jonathan P Piccini -1

机译：对于患有非瓣膜性房颤利伐沙班不劣于华法林用于预防中风或栓塞与没有差别在临床相关的出血风险
7. Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation [O] . C. van Walraven 2004

机译：Ximelagatran非逊入于预防心房颤动中的中风和全身栓塞方面

Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in nonvalvular atrial fibrillation

著录项

引文网络

相似文献

相关主题

期刊订阅